| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B | $189.89B | $179.59B | $167.94B |
| Cost of Revenue | $311.19B | $285.26B | $254.42B | $230.99B | $207.72B | $185.10B | $175.06B | $163.83B |
| Gross Profit | $10.14B | $8.70B | $7.76B | $7.60B | $6.27B | $4.79B | $4.53B | $4.11B |
| Gross Margin | 3.16% | 2.96% | 2.96% | 3.19% | 2.93% | 2.52% | 2.52% | 2.45% |
| Operating Expenses | $6.49B | $5.66B | $5.31B | $4.85B | $3.59B | $2.77B | $2.66B | $2.46B |
| Operating Income | $3.65B | $3.04B | $2.45B | $2.75B | $2.68B | $2.02B | $1.87B | $1.65B |
| Operating Margin | 1.14% | 1.03% | 0.93% | 1.15% | 1.25% | 1.07% | 1.04% | 0.98% |
| Net Income | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B | $-3.40B | $855.37M | $1.66B |
| Net Margin | 0.48% | 0.51% | 0.67% | 0.71% | 0.72% | -1.79% | 0.48% | 0.99% |
| EPS (Basic) | $8.02 | $7.60 | $8.62 | $8.15 | $7.48 | $-16.60 | $4.07 | $7.61 |
| EBITDA | $3.74B | $3.36B | $3.41B | $3.11B | $2.91B | $-4.73B | $1.65B | $1.87B |
| Stock Option Compensation Expense | $0.00 | $148.00M | $124.62M | $93.40M | $99.59M | $74.41M | $58.87M | $62.32M |
| Price To Earnings Ratio | 38.98 | 29.61 | 21.10 | 16.61 | 15.97 | -5.84 | 20.23 | 12.19 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $60.57B | $44.68B | $36.82B | $28.21B | $24.60B | $19.85B | $17.30B | $20.22B |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $76.59B | $67.10B | $62.56B | $56.56B | $57.34B | $44.27B | $39.17B | $37.67B |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $75.08B | $66.46B | $62.04B | $56.49B | $56.75B | $45.29B | $36.18B | $34.62B |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $1.51B | $645.94M | $522.00M | $-289.78M | $223.35M | $-839.64M | $2.99B | $2.93B |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.51B | $645.94M | $522.00M | $-289.78M | $223.35M | $-839.64M | $2.99B | $2.93B |
| Total Liabilities & Stockholders Equity | $76.59B | $67.10B | $62.56B | $56.56B | $57.34B | $44.27B | $39.17B | $37.67B |
| Book Value Per Share | $7.78 | $3.25 | $2.55 | $0.34 | $2.84 | $-4.98 | $14.24 | $14.00 |
| Tangible Book Value Per Share | $-82.26 | $-63.84 | $-65.91 | $-61.23 | $-66.55 | $-46.94 | $-28.58 | $-30.12 |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 2.03% | 2.25% | 2.79% | 3.00% | 2.69% | -7.68% | 2.18% | 4.40% |
| Return on Equity | 103.06% | 233.63% | 334.35% | -586.24% | 689.46% | 404.88% | 28.58% | 56.55% |
| Return on Invested Capital | 9.66% | 12.31% | 13.08% | 12.76% | 10.05% | 12.33% | 18.38% | 14.51% |
| Quick Ratio | 0.55 | 0.53 | 0.52 | 0.55 | 0.57 | 0.60 | 0.58 | 0.50 |
| Current Ratio | 0.90 | 0.88 | 0.88 | 0.91 | 0.94 | 0.98 | 0.95 | 0.93 |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B | $-3.40B | $855.37M | $1.66B |
| Depreciation | $1.06B | $1.11B | $972.39M | $697.94M | $505.17M | $401.62M | $488.54M | $499.64M |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $3.88B | $3.48B | $3.91B | $2.70B | $2.67B | $2.21B | $2.34B | $1.41B |
| Capital Expenditures | $667.98M | $487.17M | $458.36M | $496.32M | $438.22M | $369.68M | $310.22M | $336.41M |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | $437.08M | $416.17M | $398.75M | $391.69M | $366.65M | $343.58M | $338.97M | $333.04M |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | $435.47M | $1.49B | $1.18B | $483.70M | $82.15M | $420.45M | $674.03M | $639.24M |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $3.21B | $3.00B | $3.45B | $2.21B | $2.23B | $1.84B | $2.03B | $1.07B |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
Why it moved over time
Cencora reported fiscal Q3 double-digit adjusted operating income growth, $1 billion in share repurchases and raised its full-year adjusted earnings outlook, signaling stronger profitability and increased capital return.
Key fact: $1 billion in share repurchases announced
marketbeat.com: Cencora Q3 Earnings Call HighlightsCencora reported fiscal Q3 results that beat estimates and lifted its annual adjusted profit forecast on strong specialty-medicine demand, prompting a reassessment of its 2026 earnings outlook.
Key fact: Raised annual adjusted profit forecast after Q3 results beat estimates
reuters.com: Cencora lifts annual profit view on strong demand for specialty medicinesCencora reported fiscal Q3 results that beat estimates and raised its annual adjusted profit forecast on strong specialty-medicine demand, signaling improved profit momentum and firmer full-year earnings guidance.
Key fact: Raised annual adjusted profit forecast after Q3 beat driven by strong demand for specialty medicines.
reuters.com: Cencora lifts annual profit view on strong demand for specialty medicinesCencora reported Q3 adjusted EPS of $4.48, topping estimates, and raised its fiscal profit outlook as specialty-medicine demand offset GLP‑1 margin pressure — the likely catalyst for stock movement.
Key fact: Q3 adjusted EPS $4.48 vs. consensus ~$4.35; company raised its annual adjusted profit forecast on strong specialty medicines demand.
seekingalpha.com: Cencora, Inc. (COR) Q3 2026 Earnings Call TranscriptCencora's upcoming Q3 earnings, where analysts expect strength from specialty pharma, oncology expansion and margin gains, is the likely catalyst because results will clarify revenue and profit trends amid pricing and GLP-1 pressures.
Key fact: Analysts expect COR's Q3 to show specialty-pharma strength, oncology expansion and margin gains; Zacks highlights a likely earnings beat.
zacks.com: Cencora to Report Q3 Earnings: Is a Beat Likely for the Stock?Cencora is reporting Q3 earnings next week, and previews cite potential specialty‑pharma strength, oncology expansion and margin gains versus revenue pressure from pricing dynamics and GLP‑1 trends.
Key fact: Analyst previews expect specialty‑pharma strength, oncology expansion and margin improvement, even as pricing dynamics and GLP‑1 trends may pressure revenue.
zacks.com: Cencora to Report Q3 Earnings: Is a Beat Likely for the Stock?